Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (PETRA)

• ClinicalTrials.gov Identifier: NCT01805908
• Recruitment Status: Terminated
• First Posted: March 6, 2013
• Last Update Posted: June 6, 2016
• Sponsor: Ontario Clinical Oncology Group (OCOG)
• Information provided by (Responsible Party): Ontario Clinical Oncology Group (OCOG)

Study Description

Brief Summary:

The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body Single Photon Emission Computed Tomography (SPECT) imaging to predict who will respond to treatment with Trastuzumab.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Other: 111In-Pertuzumab + SPECT-CT	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer
• Study Start Date: November 2013
• Actual Primary Completion Date: June 2016
• Actual Study Completion Date: June 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: 111In-Pertuzumab + SPECT-CT; Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.	Other: 111In-Pertuzumab + SPECT-CT; 111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.

Outcome Measures

Primary Outcome Measures :

1. Change in tumour SUV (Standardized Uptake Value) from baseline to Day 8. [ Time Frame: 8 days ]
   The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 8 (Day 8 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.
2. Safety attributable to 111In-Pertuzumab injections [ Time Frame: 3 months ]
   The safety, i.e. toxicities, attributable to 111In-Pertuzumab injections will be evaluated using the National Cancer Institute (NCI) Common Termination for Adverse Events Version 4.

Secondary Outcome Measures :

1. Pharmacokinetics (PK) and tumour and normal tissue localization properties of 111In-PmAb will be measured. [ Time Frame: 3 months ]
   The pharmacokinetics of 111In-PmAb and tumour and normal tissue localization properties of 111In-PmAb will be measured. Standard PK parameters (t1/2 alpha, t1/2β, V1, Vss and CL) will be calculated.
2. Optimal mass dose of 111In-PmAb [ Time Frame: 3 months ]
   The dose of 111In-PmAb that is associated with the optimal SPECT-CT images will be established.
3. Change in tumour SUV from Baseline to Day 36 [ Time Frame: 3 months ]
   The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 36 (Day 36 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.
4. Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria. [ Time Frame: 3 months ]
   Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Metastatic, locally recurrent (local recurrence not amenable to surgical resection of curative intent), or locally advanced (T3 or T4, any N, M0) adenocarcinoma of the breast.
2. Tumour HER2 positive by immunohistochemistry for HER2 protein over-expression or by Fluorescence in situ Hybridization (FISH) for HER2 gene amplification, as defined by American Society of Clinical Oncology/College of American Pathologists guidelines
3. Initiating treatment with TmAb
4. Clinically measurable disease (by RECIST for patients with metastatic disease).

Exclusion Criteria:

1. Male gender.
2. Less than 18 years of age.
3. Life expectancy < 12 weeks.
4. Only site of metastases is liver.
5. Eastern Cooperative Oncology Group (ECOG) performance status of > 2.
6. Currently receiving PmAb or lapatinib for treatment of MBC.
7. Having received TmAb as adjuvant therapy within the previous 6 months.
8. Required to receive another radiopharmaceutical during the first week of the study.
9. Hypersensitivity to monoclonal antibodies.
10. Left Ventricular Ejection Fraction (LVEF) < 50% at baseline (within 42 days of study registration) as determined by either echocardiogram (ECHO) or Multi-Gated Acquisition (MUGA) scan.

11. Hematology and/or biochemistry parameters outside acceptable ranges:

    • absolute neutrophil count <1,500 cells/mm3,
    • platelet count <100,000 cells/mm3,
    • hemoglobin <9 g/dL,
    • total bilirubin > upper limit of normal (ULN) (unless subject has documented Gilbert's Syndrome),
    • aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase(SGOT)] and alanine aminotransferase (ALT) [serum glutamic pyruvate transaminase(SGPT)] >2.5 × ULN,
    • serum creatinine >2.0 mg/dL or 177 μmol/L,
    • alanine aminotransferase (ALP) >2.5 x ULN.
12. Known pregnancy or lactating female (e.g. positive serum beta-human chorionic gonadotropin (B-hCG) pregnancy test).
13. For women of childbearing potential, failure to agree to use a highly effective form of contraception (patient and/or partner, e.g., surgical sterilization) or two effective forms of contraception (a reliable barrier method in conjunction with spermicidal jelly, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of study treatment.
14. Any condition, which in the investigator's opinion would not make the patient a suitable candidate for inclusion in the trial.
15. Participation in another clinical trial.
16. Inability to provide informed consent.

Contacts and Locations

Locations

Canada, Ontario

Juravinski Cancer Centre

Hamilton, Ontario, Canada

Sunnybrook Odette Cancer Centre

Toronto, Ontario, Canada

Sponsors and Collaborators

Ontario Clinical Oncology Group (OCOG)

Investigators

• Principal Investigator: Mark Levine; Ontario Clinical Oncology Group, McMaster University
• Principal Investigator: Raymond Reilly; University of Toronto
• Principal Investigator: Kathleen Pritchard; Ontario Clinical Oncology Group (OCOG)

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lam K, Chan C, Done SJ, Levine MN, Reilly RM. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. Nucl Med Biol. 2015 Feb;42(2):78-84. doi: 10.1016/j.nucmedbio.2014.09.011. Epub 2014 Oct 14.

• Responsible Party: Ontario Clinical Oncology Group (OCOG)
• ClinicalTrials.gov Identifier: NCT01805908 History of Changes
• Other Study ID Numbers: OCOG-2011-PETRA
• First Posted: March 6, 2013
• Last Update Posted: June 6, 2016
• Last Verified: June 2016

Keywords provided by Ontario Clinical Oncology Group (OCOG):

metastatic; breast cancer; herceptin; imaging; tumour response; adenocarcinoma; SPECT-CT; pertuzumab; trastuzumab; locally advanced

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Trastuzumab; Pertuzumab; Antineoplastic Agents, Immunological; Antineoplastic Agents